8-K: Know Labs Announces $300,000 Registered Direct Offering of Units

Know Labs, Inc. has announced a registered direct offering of units, each consisting of one share of common stock and one warrant, with expected gross proceeds of approximately $300,000.

Summary

• Know Labs, Inc. is conducting a registered direct offering of up to 1,250,000 units.
• Each unit consists of one share of common stock and one warrant to purchase one share of common stock.
• The purchase price per unit is $0.24, with the warrant exercisable at the same price.
• The warrants expire five years from the issuance date and include a cashless exercise option under certain conditions.
• The company expects to receive gross proceeds of approximately $300,000 from the offering, before deducting fees and expenses.
• Boustead Securities, LLC is acting as the placement agent for the offering and will receive a cash fee of 7% of the gross proceeds.
• The placement agent will also receive a warrant to purchase 7% of the units offered, exercisable at $0.24 per share.
• Benchmark Company, LLC has waived its right to act as an investment banker for this offering in exchange for a 3.5% cash fee.
• The net proceeds from the offering will primarily be used for product development of the KnowU glucose monitoring products, sales and marketing, clinical studies, intellectual property development, and general operating expenses.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. While the capital raise is positive for funding operations, the dilution and fees are negatives. The focus on product development is a positive sign for the future.

Positives

• The offering provides Know Labs with additional capital to fund its operations and product development.
• The use of proceeds is primarily focused on advancing the KnowU glucose monitoring product, which is a key focus for the company.
• The offering is structured with warrants that could provide additional capital if exercised in the future.

Negatives

• The offering is dilutive to existing shareholders.
• The company is paying significant fees to placement agents and advisors, reducing the net proceeds.
• The company has broad discretion in how it uses the net proceeds, which may not align with all investors' expectations.

Risks

• The company's management has broad discretion in the use of the net proceeds, which may not be used as investors expect.
• The company's future success depends on the development and commercialization of its products, which is subject to regulatory approvals and market acceptance.
• The company may need to raise additional capital in the future, which could further dilute existing shareholders.
• The company's technology is still in development and may not achieve the desired results.

Future Outlook

The company intends to use the net proceeds from the offering primarily to continue product development of the KnowU glucose monitoring products, including sales and marketing efforts and clinical studies, intellectual property development, and for operating expenses and working capital purposes. The company may also invest the net proceeds in short-term, interest-bearing, investment-grade securities pending their final application.

Management Comments

• The company's management will have broad discretion in the way that we use the net proceeds of this offering and we may use the proceeds for purposes that are not contemplated at the time of the Offering.

Industry Context

This offering is a common method for small, developing companies to raise capital. The focus on glucose monitoring aligns with the growing market for non-invasive health monitoring technologies.

Comparison to Industry Standards

• The structure of the offering, with units consisting of common stock and warrants, is a typical approach for small-cap companies seeking capital.
• The fees paid to placement agents and advisors are within the typical range for such offerings.
• The use of proceeds for product development and clinical studies is consistent with the needs of a company in the medical device sector.
• Comparable companies in the medical device space often use similar methods to raise capital for research and development.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The company will have additional capital to fund its operations and product development, which could benefit employees and customers in the long term.
• The offering could lead to increased market awareness of the company and its products.

Next Steps

• The company will file a final prospectus supplement with the SEC.
• The company will deliver the units to investors after receiving payment.
• The company will use the net proceeds for product development, sales, marketing, clinical studies, and operating expenses.

Key Dates

Keywords

registered direct offering, common stock, warrants, glucose monitoring, Know Labs, capital raise, placement agent, Boustead Securities, Benchmark Company, KnowU